Surmodics Inc stock (US88025U1097): Former chair Susan Knight joins peer Anteris board

Susan Knight, who chaired Surmodics Inc's board until November 2025, was appointed to Anteris Technologies' board, highlighting her expertise in medical devices. Surmodics stock closed at 42.98 USD on Nasdaq as of May 12, 2026.

Susan Knight, former board chair of Surmodics Inc until November 2025, joined the board of Anteris Technologies Global alongside Stephen Denaro. The appointments were announced ahead of Anteris' 2026 annual stockholder meeting, according to Investing.com as of May 2026. Knight's extensive experience in the medical device sector underscores ongoing leadership transitions in the industry.

Surmodics Inc stock traded at 42.98 USD on May 12, 2026, on Nasdaq, according to TradingKey as of 05/12/2026. The company remains focused on its core operations amid peer developments.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Surmodics Inc
• Sector/industry: Medical devices
• Headquarters/country: United States
• Core markets: US healthcare
• Key revenue drivers: Surface modification technologies
• Home exchange/listing venue: Nasdaq (SRDX)
• Trading currency: USD

Surmodics Inc: core business model

Surmodics Inc develops and manufactures surface modification and delivery systems for medical devices. The company provides technologies that enhance device performance, including hydrophilic coatings and drug delivery platforms used in cardiovascular and peripheral vascular applications. These solutions help improve patient outcomes by reducing complications in procedures.

Headquartered in Eden Prairie, Minnesota, Surmodics serves major medical device original equipment manufacturers (OEMs). Its business model centers on research-driven innovation, with a focus on proprietary biomaterials that address unmet clinical needs, according to its investor relations site as of 2026.

Main revenue and product drivers for Surmodics Inc

Surmodics generates revenue primarily from its Medical Device unit, which includes coatings like the Surmodics Stability hydrophilic coating for guidewires and catheters. The company's drug delivery platforms, such as the Surmodics Sirolimus-coated balloon, target treatments for peripheral artery disease. These products drive growth through partnerships with leading device makers.

Additional revenue comes from biomedical research services and royalties. The firm reported ongoing development in combination device technologies, positioning it in the expanding US interventional cardiology market valued for its role in treating chronic conditions.

Industry trends and competitive position

The medical device coatings market is growing due to rising demand for minimally invasive procedures in the US. Surmodics competes with players like Kraton and DSM by emphasizing lubricious coatings that enable smoother device navigation. Its focus on drug-eluting technologies aligns with trends toward localized therapies reducing systemic side effects.

Why Surmodics Inc matters for US investors

Listed on Nasdaq, Surmodics offers US investors exposure to the domestic medtech sector, which benefits from strong healthcare spending. With operations centered in Minnesota, the company taps into the US economy's innovation hubs and regulatory environment via FDA approvals, making it relevant for portfolios tracking healthcare innovation.

Conclusion

Surmodics Inc continues to advance its medical device technologies amid industry leadership changes, such as Susan Knight's move to Anteris Technologies. With a stable share price near 43 USD on Nasdaq and a focus on high-growth coatings, the company maintains its position in US healthcare innovation. Investors monitor peer dynamics and product pipelines for broader sector insights.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.